T
Thomas Marbury
Researcher at University of Florida
Publications - 144
Citations - 3754
Thomas Marbury is an academic researcher from University of Florida. The author has contributed to research in topics: Pharmacokinetics & Renal function. The author has an hindex of 32, co-authored 135 publications receiving 3331 citations. Previous affiliations of Thomas Marbury include University of Houston.
Papers
More filters
Journal ArticleDOI
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
TL;DR: It is concluded that olmesartan, at its starting dose, is more effective than the starting doses of the other ARBs tested in reducing cuff diastolic blood pressure in patients with essential hypertension.
Journal ArticleDOI
Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis.
Xiaoli Wang,Giridhar S. Tirucherai,Thomas Marbury,Jessie Wang,Ming Chang,Donglu Zhang,Yan Song,Janice Pursley,Rebecca A. Boyd,Charles Frost +9 more
TL;DR: In conclusion, ESRD resulted in a modest increase in apixaban AUC and no increase in Cmax, and hemodialysis had a limited impact on Apixaban clearance.
Journal ArticleDOI
Clinical improvement in psoriasis with specific targeting of interleukin-23
Tamara Kopp,Elisabeth Riedl,Christine Bangert,Edward P. Bowman,Elli K. Greisenegger,Ann Horowitz,Harald Kittler,Wendy M. Blumenschein,Terrill K. McClanahan,Thomas Marbury,Claus Zachariae,Danlin Xu,Xiaoli Shirley Hou,Anish Mehta,Anthe S. Zandvliet,Diana Montgomery,Frank van Aarle,Sauzanne Khalilieh +17 more
TL;DR: Tildrakizumab demonstrated important clinical improvement in moderate-to-severe psoriasis patients as demonstrated by improvements in PASI scores and histological samples, suggesting that specific targeting of IL-23p19 results in symptomatic improvement of disease severity in human subjects.
Journal ArticleDOI
Effect of Renal Insufficiency on the Pharmacokinetics of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor
Arthur J. Bergman,Josee Cote,Bingming Yi,Thomas Marbury,Suzanne K. Swan,William K. Smith,Keith Gottesdiener,John A. Wagner,Gary A. Herman +8 more
TL;DR: Sitagliptin is an oral, once-daily, potent, and highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Journal ArticleDOI
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.
Richard E. Nettles,Min Gao,Marc Bifano,Ellen Chung,Anna Persson,Thomas Marbury,Ronald Goldwater,Michael Demicco,Maribel Rodriguez-Torres,Apinya Vutikullird,Ernesto Fuentes,Eric Lawitz,Juan Carlos Lopez-Talavera,Dennis M. Grasela +13 more
TL;DR: BMS‐7590052 is the first NS5A replication complex inhibitor with multiple dose proof‐of‐concept in clinic well tolerated, had a PK profile supportive of once‐daily dosing, and produced a rapid and substantial decrease in HCV‐RNA levels in patients chronically infected with HCV genotype 1.